Comparison of 2 Human Chorionic Gonadotropin Immunoassays Commercially Available for Monitoring Patients With Gestational Trophoblastic Disease

Souza, J. M.; Braga, Antônio; Santos, Rafael Sanches Dos; Ramos, Marcos Montanha; Charry, R; Maestá, Izildinha

doi:10.1097/igc.0000000000001042

Cited by 2 publications

(1 citation statement)

References 24 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After uterine evacuation of molar pregnancy, all patients underwent clinical and laboratory follow-up at 7–14 days intervals with quantitative serum hCG testing using an electrochemiluminescent immunoassay (DPC Immulite, Siemens, Los Angeles, CA, USA) until remission of the disease. 23 After that, testing continued monthly for at least 6 more months, in case of maintained spontaneous remission of the disease, or for 12 months, in cases of remission after treatment of GTN. The patients were then discharged from postmolar follow-up and were told they might try to become pregnant again.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of High-Dose Vitamin A Treatment in Postmolar Patients with Low and Plateauing Serum Human Chorionic Gonadotropin Levels

Uberti

Diaz

Cardoso

et al. 2020

Rev Bras Ginecol Obstet

Self Cite

View full text Add to dashboard Cite

Objective To compare the effect of high-dose vitamin A (HD Vit-A) use during postmolar follow-up of patients with low and plateauing (L&P) serum human chorionic gonadotropin (hCG) levels, from the moment serum hCG plateaued (P-hCG) to the first normal serum hCG value (< 5 IU/L). Methods The present retrospective series case study compared two nonconcurrent cohorts of patients. Control group (CG): 34 patients with L&P serum hCG levels who underwent expectant management for 6 months after uterine evacuation, from 1992 to 2010; study group (SG): 32 patients in similar conditions who received 200,000 IU of Vit-A daily, from the identification of a P-hCG level to the first normal hCG value or the diagnosis of progression to gestational trophoblastic neoplasia (GTN), from 2011 to 2017. The present study was approved by the Ethics Committee of the institution where it was conducted. Results In both groups, the prevalence of persistent L&P serum hCG levels was < 5%. In the SG, hCG levels at plateau were higher (CG = 85.5 versus SG = 195 IU/L; p = 0.028), the rate of postmolar GTN was lower (CG = 29.4% versus SG = 6.3%, p = 0.034) and follow-up was shorter (CG = 14 versus SG = 10 months, p < 0.001). During GTN follow-up, there were no differences in GTN staging or treatment aggressiveness in both groups. High-dose Vit-A use did not have any relevant toxic effect. There were no GTN relapses or deaths. Conclusion The limited use of HD Vit-A seems to have a safe and significant effect on the treatment of postmolar patients with L&P serum hCG levels and may decrease the development of postmolar GTN in this population.

show abstract

Section: Methodsmentioning

confidence: 99%